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Abstract
Background: Genomic biomarkers play an increasing role in both preclinical and clinical application. Development
of genomic biomarkers with microarrays is an area of intensive investigation. However, despite sustained and
continuing effort, developing microarray-based predictive models (i.e., genomics biomarkers) capable of reliable
prediction for an observed or measured outcome (i.e., endpoint) of unknown samples in preclinical and clinical
practice remains a considerable challenge. No straightforward guidelines exist for selecting a single model that will
perform best when presented with unknown samples. In the second phase of the MicroArray Quality Control
(MAQC-II) project, 36 analysis teams produced a large number of models for 13 preclinical and clinical endpoints.
Before external validation was performed, each team nominated one model per endpoint (referred to here as
‘nominated models’) from which MAQC-II experts selected 13 ‘candidate models’ to represent the best model for
each endpoint. Both the nominated and candidate models from MAQC-II provide benchmarks to assess other
methodologies for developing microarray-based predictive models.
Methods: We developed a simple ensemble method by taking a number of the top performing models from
cross-validation and developing an ensemble model for each of the MAQC-II endpoints. We compared the
ensemble models with both nominated and candidate models from MAQC-II using blinded external validation.
Results: For 10 of the 13 MAQC-II endpoints originally analyzed by the MAQC-II data analysis team from the
National Center for Toxicological Research (NCTR), the ensemble models achieved equal or better predictive
performance than the NCTR nominated models. Additionally, the ensemble models had performance comparable
to the MAQC-II candidate models. Most ensemble models also had better performance than the nominated
models generated by five other MAQC-II data analysis teams that analyzed all 13 endpoints.
Conclusions: Our findings suggest that an ensemble method can often attain a higher average predictive
performance in an external validation set than a corresponding “optimized” model method. Using an ensemble
method to determine a final model is a potentially important supplement to the good modeling practices
recommended by the MAQC-II project for developing microarray-based genomic biomarkers.
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Background
Gene expression microarrays have been applied in var-
ious fields [1-6]. Despite widespread usage, the transla-
tion of basic findings to clinical utility such as diagnosis
and prognosis has been slow. This is largely due to the
fact that some clinical endpoints are difficult to predict
with microarrays, such as prediction of drug-induced
liver injury [7], and survival endpoints for many cancers
[8]. In addition, issues such as small sample size, low
signal-to-noise ratio and lack of a fully annotated tran-
scriptome contribute to the lack of success in develop-
ing biomarkers (i.e., predictive models or classifiers)
with microarrays [9,10].
The conventional procedure of developing a microar-
ray-based biomarker involves a selection process to
identify one classifier out of many others generated in
this process for application to an external dataset. The
selection is largely dependent on the accuracy estima-
tion [11]. Specifically, the “optimized” model is selected
using the training set with, for example, cross-validation
to estimate its predictive performance. Some authors
argue that cross-validation can provide an unbiased esti-
mate of performance when properly applied [12,13]
while others point out that the variability in the error
estimation can be very high when cross-validation is
applied to datasets with small sample sizes [14]. Thus,
there exists a great uncertainty that an accuracy-based
model selection procedure will choose the best microar-
ray-based classifier [12,15].
Selecting a single optimized model is the most com-
mon approach to developing microarray-based predic-
tive models [6,16-18]. However, it is being challenged
given the fact that many models with similar statistical
performance are often identified for a studied endpoint.
By reanalyzing the breast cancer prognosis dataset
reported by van’t Veer et al.[8], Ein-Dor et al. noticed
that many gene sets gave nearly equal prediction accu-
racy [19]. The question is whether the combination of
these well performing models could be preferable to an
accuracy-based selection of a single optimized model
from among many.
Ensemble methods have been demonstrated its usage
in some fields such as machine learning [20] and Quan-
titative Structure Activity Relationships (QSAR) [21].
These investigations are carried out under the hypoth-
esis that the methods likely capture a greater diversity of
potentially informative features [21] that might improve
the model robustness when included. Ensemble methods
have similarly been explored in gene expression studies
[22,23]. It was found that enhanced prediction accuracy
for ensemble methods compared to the single model
selection method, especially for complex and/or hetero-
geneous endpoints. However, the comparative analysis
was carried out on limited datasets sometimes having
small sample sizes. A rigorous comparison where find-
ings can be generalized is best achieved with a systema-
tic comparative analysis using multiple datasets
containing endpoints with different characteristics. The
second phase of MicroArray Quality Control (MAQC-
II) project, led by the U.S. Food and Drug Administra-
tion with broad participation from the large research
community, offers the benchmark data to allow such a
rigorous comparison.
One goal of the MAQC-II project was to develop
baseline practices for the application of microarray tech-
nology to biomarker development [24]. This process
took nearly four years to enable a full investigation of
the impact of modeling procedure choices on the quality
of predictive models. The project provides the requisite
datasets as well as a large number of validated models
developed using diverse methods for comparison. Speci-
fically, the 36 analysis teams generated more than
30,000 models across 13 endpoints from six datasets.
Importantly, similar prediction performance was
attained despite the use of different modeling algorithms
and gene sets. However, the MAQC-II required each
team to first nominate and then validate in blinded
manner a single model (or nominated model) for each
endpoint. A group of experts then selected 13 final
models (one per endpoint) that were designated candi-
date models. The performance of these selected ‘opti-
mized’ models (both nominate and candidate models)
was assessed on blinded, independent validation sets.
The comprehensive and disciplined process employed
by this approach in selecting optimized models resulted
in a set of nominate and candidate models constituting
sound benchmarks for comparison of ensemble
methods.
In this study we applied a simple ensemble approach
of combining the top 50% of all the models from the
selected MAQC-II team and compared them with the
nominated and candidate models for each endpoint
(More details can be found in Results.). In other words,
we took the simplest way to generate ensemble models
and then compare them with the optimized models gen-
erated from the most sophisticated and comprehensive
approaches implemented in MAQC-II. Our study indi-
cates that even such simple ensemble methods can
achieve comparable if not better predictive performance
in external validation sets than the corresponding single
“optimized” model from MAQC-II.
Methods
Datasets
All six MAQC-II datasets were used for this study [24].
Three datasets are related to toxicogenomics endpoints:
lung tumorigenicity from Thomas, et al.[25], non-geno-
toxicity in the liver from Fielden et al.[26], and liver
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toxicity from the Lobenhofer et al.[27]. The remaining
three datasets are related to cancer prognosis for breast
cancer [28], multiple myeloma [29,30], and neuroblas-
toma [31]. Together they contain 13 preclinical and clin-
ical endpoints, designated A through M, as shown in
Table 1. Endpoints I and M are “disguised” negative
controls with randomly assigned classes, and endpoints
H and L are “disguised” positive controls representing
patient sex; “disguised” indicates here that the MAQC-II
analysis teams did not know the nature of these end-
points. There are three preclinical endpoints assessing
toxicity (A, B and C), and six clinical endpoints (D, E, F,
G, J and K) representing patient responses in breast can-
cer, multiple myeloma or neuroblastoma. The training
sets were provided to the analysis teams to develop
models using the known labels. Once all the analysis
teams had developed the final models and frozen them,
the validation sets were released with blinded labels.
Details about the datasets, the experimental design and
timeline of the MAQC-II project are discussed by Shi,
et al.[24].
Data analysis protocol of NCTR models
The analysis team from the National Center for Toxico-
logical Research (NCTR) was one of the 36 analysis
teams in the MAQC-II consortium. The models used in
this study were those generated during the MAQC-II
process with no retroactive modification. This section
describes the original analysis that was done as depicted
in Figure 1 flowchart. The center mean shift approach
was applied to correct potential batch effect. For data-
sets having a skewed class ratio greater than four, the
class distribution was balanced by over sampling the
minority class to attain an even distribution. The two
statistical methods, fold change plus p-value (from a
simple t-test) and Significance Analysis of Microarrays
(SAM) [32], were used for feature selection beginning
with the training datasets. In the fold change plus p-
value method, the features were chosen by first ranking
genes by absolute fold change, and then excluding all
features that did not satisfy p-value <0.05. The top five
features were included first in the cross-validation (CV)
and the process was then repeated by incrementally
adding five features more at each step until the number
of features reached 200. In the SAM method, a relative
difference defined in the SAM algorithm was applied to
rank the features, followed by a feature selection
approach analogous to fold-change plus p-value. We
applied two different classification methods, k-nearest
neighbors (KNN) and Naive Bayes modeling, to develop
models for each of the 13 endpoints. For a range of
parameter values, 8320 models were developed and sub-
mitted to the MAQC-II consortium, including 7280
KNN models (i.e., 13 endpoints × 40 features sets × 2
feature selection methods × 7 parameters of K) and
1040 Naïve Bayes models (i.e., 13 endpoints × 40 fea-
tures sets × 2 feature selection methods). The classifica-
tion methods were applied using R [33] and the klaR
package [34].
Selection of NCTR nominated models
A complete 5-fold CV procedure was employed to
determine the number of features and modeling para-
meters used to develop the final classifier. The com-
plete CV embeds the entire modeling process
including, batch correction, resizing training set and
feature selection in each of the cross-validation steps.
The average performance of the classifiers from the 50
Table 1 The datasets used in MAQC-II project
Endpoint code Endpoint Endpoint description Training set Validation set
#Sample P/N ratio* #Sample P/N ratio
A Lung tumorigenicity Lung tumorigen vs. non-tumorigen 70 0.59 88 0.47
B Non-genotoxicity Non-genotoxic hepatocarcinogen vs. non-carcinogen 216 0.51 201 0.4
C Liver toxicity Liver toxicants vs. non-toxicants 214 0.58 204 0.62
D Breast cancer Pathologic complete response, pCR 130 0.34 100 0.18
E Breast cancer Estrogen receptor status (ER +/-) 130 1.6 100 1.56
F Multiple myeloma Overall survival 340 0.18 214 0.14
G Multiple myeloma Event-free survival 340 0.33 214 0.19
H Multiple myeloma Male vs. female (positive control) 340 1.33 214 1.89
I Multiple myeloma Random 2-class label (negative control) 340 1.43 214 1.33
J Neuroblastoma Overall survival 238 0.1 177 0.28
K Neuroblastoma Event-free survival 239 0.26 193 0.75
L Neuroblastoma Male vs. female (positive control) 246 1.44 231 1.36
M Neuroblastoma Random 2-class label (negative control) 246 1.44 253 1.36
* P/N = Positive/Negative ratio. Positive denotes for these samples showing the positive results (e.g. cancer, tumor).
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CV runs was calculated and the parameters that
resulted in the best classifier were used for developing
the final classifier using the entire training set. As
recommended by the MAQC-II consortium [24], MCC
(Mathhews Correlation Coefficient) was the selected
metric for assessing model performance. An MCC-
guided method was used to identify the models to be
submitted for each endpoint, which consisted of a
hierarchical decision tree with a knowledge justifica-
tion at each level of the decision. Specifically, the fol-
lowing step was used:
• Step 1 – Decision based on the MCC value: The
MCC value was adjusted to one decimal precision and
models with the same MCC value were grouped. For
example, models with MCC values of 0.89 and 0.91
were considered as performing equally and placed into
the MCC > 0.9 group. The models in the group with
the highest MCC value were passed to the next step.
• Step 2 – Decision based on the number of features:
Within a group of models with the same MCC value,
more parsimonious models were given higher priority.
However, if two models contained nearly the same num-
ber of features, then accuracy, sensitivity and specificity
were used to choose the best performing model.
• Step 3 – Decision based on the feature selection
method: For equally well-performing models, those that
used SAM for feature selection were chosen over those
that used fold change plus p-value.
• Step 4 – Decision based on the classification
method: For equally well-performing models those cre-
ated using KNN were selected over those created using
a Naive Bayes classifier.
Ensemble method
An ensemble model was developed for each endpoint
for comparison to those submitted for MAQC-II
Figure 1 Overview of the NCTR model development process.
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evaluation. An ensemble model was derived by taking
the 50% of the models from cross-validation with the
highest MCC and using a voting process to make a final
prediction about a sample. To begin, the average per-
centage of positive predictions for the 50% of models in
the training set is recorded. For each sample in the vali-
dation set, the percentage of models producing a posi-
tive prediction is calculated. This percentage is then
divided by the average percentage of positive predictions
in the training set recorded earlier. If the ratio of these
numbers is one or greater, the ensemble model will pro-
duce a positive prediction. Otherwise the ensemble
model will give a negative prediction. External validation
was done while blinded to the class of the external test
sets as implemented in MAQC-II.
Results
As one of the 36 analysis teams involved in the MAQC-
II project, we generated 8320 models (7280 KNN mod-
els and 1040 Naïve Bayes models). As shown in Addi-
tional file 1, the correlation coefficient (r=0.927) of our
submitted models in the external validation was higher
than that from all the MAQC-II models (r=0.840) [24],
indicating that the performance of our models was
above the average among the 36 analysis teams. We also
selected one model per endpoint (called the NCTR
nominated models) from all the NCTR models using
the accuracy-based selection method (refer to the Meth-
ods sections for more details). Meanwhile, each analysis
team that participated in the project also nominated one
model for each endpoint they analyzed according to the
MAQC-II guidance. An MAQC-II expert committee
then selected 13 candidate models, representing the best
model for each endpoint from all the submitted models
from the 36 teams, before external validation was per-
formed. In this study, the ensemble models comprising
of 50% of all the NCTR models with highest perfor-
mance in cross-validation are against both the NCTR
nominated models as well as the MAQC-II candidate
models across all the 13 endpoints. To validate the find-
ings from the NCTR-centric practice, the same analysis
was carried out on the models generated by other analy-
sis teams. Comparative assessment was based on the
blinded external validation performance.
The NCTR ensemble models vs. the NCTR nominated
models
As shown in Figure 2, using MCC as the performance
metrics we found that for 10 of the 13 endpoints, the
ensemble model achieved a better or equal MCC value
than the NCTR nominated model. The pair-wise t-test
indicated that the average MCC of the ensemble models
was significantly higher than the average from the
NCTR-nominated models (P-value = 0.039 if two ran-
dom endpoints, i.e., I and M, were excluded).
We also compared the MCC of the NCTR nominated
models and the NCTR ensemble models in the external
validation sets to that of the full set of developed models
(N=8320). The box plots in Figure 3 show the MCC dis-
tribution for these models for each of the 13 endpoints,
with the NCTR nominated model shown as a green dia-
mond and the ensemble model shown as a red square.
For a well-performing model selection method either
the “optimized” or the ensemble model or both should
Figure 2 The ensemble models vs. the NCTR nominated
models. A pair-wise t-test was applied to the MCCs obtained from
the ensemble models and the NCTR nominated models. (P-value =
0.039 if two random endpoints, i.e., I and M, were excluded).
Figure 3 The ensemble models and the NCTR nominated
models related to all the NCTR developed models. The
distribution of the cross-validation MCCs from 8320 NCTR
developed models for each endpoint was shown in the box plots;
the NCTR nominated models were marked as the green diamonds,
and the ensemble models were marked as the red squares.
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be better than the median MCC in the external valida-
tion set for the full set of developed models for a parti-
cular endpoint. For the endpoints C, D, E, G, J, and K,
the NCTR nominated models showed an MCC below
the median value of all developed models. In contrast,
none of the ensemble models had an MCC below the
median value. Moreover, the MCCs of the ensemble
models for endpoints of C, D, E, F, G, H, K, and L
ranked in the top 25% of values from all selected mod-
els, and those for endpoints of A, B, and J also ranked
above the median value of all developed models. This is
a strong evidence that the ensemble models provides
more consistent performance in the external validation
set than the NCTR nominated models selected based on
the accuracy.
The NCTR ensemble models vs. the MAQC-II candidate
models
We compared the NCTR ensemble models with the
MAQC-II candidate models. The candidate model for
each endpoint was selected by the MAQC-II expert
group from among the nominated models submitted by
the 36 data analysis teams before the external validation,
which represented the best practice to select an “opti-
mized” model. As shown in Figure 4, there is no signifi-
cant difference in the average MCC values between the
NCTR ensemble models and the candidate models (P-
value = 0.43 from a pair-wise t-test), indicating that the
simple ensemble method used in this study can achieve
equivalent performance of those selected by the experts.
The comparative analysis of models from different MAQC-
II analysis teams
We performed the same comparative analysis for the
models generated by other analysis teams. We selected
only those teams that analyzed all 13 endpoints and
submitted more than 260 models. This resulted in only
5 teams (DAT7, DAT19, DAT20, DAT25, and DAT29
as denoted by the consortium). We generated the
ensemble models for each endpoint modeled by each
team and the results were compared with their nomi-
nated models as well as the candidate models. The aver-
age MCC from the 11 non-random endpoints (i.e.,
excluding endpoints I and M) was used for the compari-
son. As depicted in Figure 5, most ensemble models
performed better than the corresponding nominated
models. The exceptions were DAT20 and DAT25 as
they demonstrated similar performance of the ensemble
and nominated models.
Discussion
Microarray-based models to predict preclinical and clin-
ical endpoints have become routine in research. Most
studies focus on the selection of a single “optimized”
model, but it is never clear whether that model will pro-
vide acceptable performance on an external validation
set. Given the fact that many models from the same
training set could achieve similar predictive perfor-
mance, we investigated a simple ensemble approach of
combining the top 50% best performing models and
compared it with the single model selection approach.
We conducted the investigation using the MAQC-II
results because the MAQC-II project (1) covers a
diverse set of endpoints including both “disguised” posi-
tive and negative controls, offering an opportunity to
examine the issue in a systematic fashion; (2) generated
the results from the blinded validation sets with large
sample sizes, an important criterion to ensure the valid-
ity of the investigation; (3) provides the nominated mod-
els from each of 36 analysis teams, which represents a
Figure 4 The ensemble models vs. MAQC-II candidate models. A
pair-wise t-test was applied to the MCCs obtained from the ensemble
models and the MAQC-II candidate models (P-value = 0.43).
Figure 5 The comparison of the models from different analysis
teams. The average MCC was calculated from 11 non-random
endpoints in the external validation sets when I and M were
excluded.
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broad range of model selection methods; and (4) yielded
the MAQC-II candidate models, representing the “best
practice” of developing classifiers using the model selec-
tion method.
Using the MAQC-II results from the NCTR team and
validated by the results from other five MAQC-II data
analysis teams, two important observations were made.
First, within each team, the ensemble method consis-
tently generated models performing better in the exter-
nal datasets than the model selection methods
implemented by different teams. Second, the ensemble
method performed comparably to the MAQC-II candi-
date models that were chosen with considerable efforts.
The results demonstrate that identification of a single
best model solely based on the statistical performance is
difficult as exemplified in the MAQC-II nominated
models where knowledge and experience behind the
model selection is crucial as practiced in the determina-
tion of the MAQC-II candidate models. The proposed
ensemble approach is easy, objective and reproducible,
and thus can be an alternative method to generate a
robust model based on the training set.
Accuracy estimation of a classifier using only a train-
ing set is still a difficult issue due to over-fitting, which
is one of the major limitations associated with predictive
models. Models often have excellent performance in the
training dataset but nonetheless poorly predict in exter-
nal validation datasets, even when best modeling prac-
tices are employed. The inconsistent predictive
performance between the training set and testing set
stems from the influence of idiosyncratic associations
between features and endpoints in the training set.
Cross-validation is a common method to account for
these idiosyncrasies and to estimate accurately the pre-
diction error of the models. Simon et al. proposed that
the cross-validation, if used properly [13], provides a
nearly unbiased estimate of the true error of classifica-
tion procedure, while incomplete cross-validation will
result in a seriously biased underestimate of the error
rate. From our experience in the MAQC-II consortium,
we found that the accuracy based selection process,
even using the complete cross-validation procedure, still
lead to models that are apparently over-fit and perform
poorly on the external datasets (Additional file 2). In
other words, a degree of over-fitting still exists even
after properly applying “complete” cross-validation. This
demonstrates that reducing the risk of over-fitting is still
an issue in the selection method that must be addressed
in order to improve the performance of microarray-
based predictive models.
In this study, during cross-validation it was observed
that many models could attain similar performance,
while the models that produced the best MCCs in the
training sets did not necessarily provide the best MCCs
in the external validation sets. Based on these observa-
tions, it is reasonable to assume that an ensemble mod-
eling method could substantially mitigate the risk of
over-fitting presented in the “optimized” model selection
process, although the ensemble models could not always
generate the best predictive model.
Ensemble models have been well studied in the
machine learning area where they have been shown use-
ful for improving prediction performance [35]. Random
forest is a representative algorithm that consists of
many decision trees that vote to select class member-
ship. Some authors also reported that ensemble methods
have worked well in QSAR models [21,36] and microar-
ray-based studies [22,23] with a small number of data-
sets, but a literature search did not produce any
comprehensive evaluations of the utility of ensemble
methods in microarray-based classifier development.
The MAQC-II study participants did not determine a
preferred approach to select a best model for each end-
point, leaving that selection as part of an individual
team’s preference. The data reported here did support
this conclusion; in 8 of the 11 non-random endpoints (i.
e., excluding endpoints I and M) the ensemble models
were ranked in the top 25% of MCC values from all of
the developed models.
It should also be noted that the choice to use the
top 50% models based on cross-validation for the
ensemble models was arbitrary. The data from further
experiments shown in Additional file 3 have suggested
that the choice of the number of models to be com-
bined does not greatly affect performance of an
ensemble model as long as a sufficient number of
models (e.g., > 10% models) are retained in the pro-
cess. The combination of too many models will actu-
ally decease slightly the performance, likely because of
the noise introduced by the models with relatively
poor performance. In contrary, using too few models
does not have too much value due to the lack of
representative models in ensemble. Therefore, we sug-
gest that a modest number of models should be
retained for ensemble calculation.
Many factors affect the performance of the microar-
ray-based classifiers. The MAQC-II consortium compre-
hensively evaluated most of these factors through a
community-wide practice, and established good model-
ing practice guidelines [24]. This study provides a fol-
low-up and extension of the MAQC-II team efforts. We
found that an ensemble modeling procedure can reduce
the risk of over-fitting and provides stable and robust
predictive power than those single “optimized” models.
These findings provide a necessary supplement to the
good modeling practices for developing microarray-
based predictive classifiers developed in the MAQC-II
process.
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Disclaimer
The views presented in this article do not necessarily
reflect those of the US Food and Drug Administration.
Additional material
Additional file 1: Internal cross-validation vs. external validation of
the 8320 NCTR developed models. The Pearson correlation of MCCs
from Internal cross-validation vs. external validation is 0.927.
Additional file 2: Internal cross-validation vs. external validation of
the NCTR nominated models.
Additional file 3: The average MCCs vs. the percentages of the top
models for ensemble calculation. The average MCC was calculated
from 13 endpoints in the external validation set; the top models were
selected based on the MCCs from internal cross-validation in the training
set.
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MAQC: MicroArray Quality Control; NCTR: National Center for Toxicological
Research; QSAR: Quantitative Structure Activity Relationship; SAM:
Significance Analysis of Microarrays; CV: Cross-validation; KNN: K-nearest
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